#USA #San Diego #Neurocrine Biosciences #Tardive Dyskinesia #Carnie Wilson

Neurocrine Biosciences Partners with Carnie Wilson for Awareness Campaign

Neurocrine Biosciences, Inc. has recently announced a crucial initiative aimed at raising awareness about Tardive Dyskinesia (TD) through a multimedia campaign called ConnectING with Carnie. This campaign is spearheaded by renowned singer and mental health advocate Carnie Wilson. With her own significant experiences surrounding mental health, Carnie aims to bring attention to the struggles of those dealing with TD – a condition characterized by involuntary, repetitive movements often resulting from long-term use of antipsychotic medications.

Campaign Goals

The primary goal of ConnectING with Carnie is to empower individuals living with Tardive Dyskinesia to overcome stigma. The campaign encourages people to engage in honest discussions about their symptoms without fear of embarrassment. It also emphasizes the importance of consulting healthcare professionals regarding appropriate treatment options available to them.

Carnie Wilson, who has not personally experienced TD, acknowledges the importance of advocacy following profound conversations with mental health leaders and those living with TD. She shared her motivations, stating, “Mental health is a topic close to my heart. I want people who might be struggling with tardive dyskinesia to know they do not need to suffer in silence.” Through this campaign, Carnie plans to connect not only with individuals affected by TD but also with their care partners, fostering a supportive community.

Personal Stories and Resources

The campaign will feature a series of videos that showcase personal stories of resilience and courage in the face of TD. These stories serve to highlight the experiences of individuals who have undergone diagnosis and treatment, alongside discussions about potential treatment options, including INGREZZA® (valbenazine) capsules. This FDA-approved medication is a key focus of the campaign, promoting a proactive approach to managing TD.

Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences, expresses enthusiasm for the partnership, stating, “Our goal for ConnectING with Carnie is to reduce stigma, increase understanding, and encourage individuals with involuntary movements to consult a healthcare provider for appropriate diagnosis and treatment options.”

Raising Awareness and Addressing Stigma

Approximately 800,000 adults in the U.S. are estimated to suffer from Tardive Dyskinesia, often causing disruptions in their daily lives as well as negatively impacting interactions and personal well-being. Through ConnectING with Carnie, Neurocrine seeks to elevate awareness toward this under-discussed condition and motivate those affected to pursue necessary medical advice. With Carnie's infectious enthusiasm and advocacy, the campaign aims to foster a safe space for dialogue and support.

The campaign will leverage various platforms, including Carnie’s own, to reach a broader audience. Resources will be hosted on ConnectingWithCarnie.com, where individuals can find informative content about TD and hear stories of others who have navigated difficult health journeys.

Conclusion

ConnectING with Carnie stands as a significant beacon for individuals living with Tardive Dyskinesia, better equipping them with the courage to speak out and advocate for their wellbeing. By shedding light on mental health conditions not often discussed, Neurocrine Biosciences and Carnie Wilson are making strides toward a more supportive environment for those affected by TD, ultimately aiming to bring stigma to light and encourage much-needed understanding and dialogue.